Vera Therapeutics director granted 17,084 stock options
Vera Therapeutics director Scott W. Morrison received a grant of stock options covering 17,084 shares of Class A common stock.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Vera Therapeutics director Scott W. Morrison received a grant of stock options covering 17,084 shares of Class A common stock. The options have an exercise price of $34.35 per share and vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 annual stockholder meeting, or sooner upon a change in control, subject to his continued service. After this grant, he holds options on 17,084 shares directly.
Insider Trade Summary
Grant/Award: 17,084 shares
Grant/Award
1 txn
Insider
Morrison Scott W
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 17,084 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 17,084 contracts (Direct)
Footnotes (1)
- F1. The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control.
Key Figures
Option grant size: 17,084 shares
Exercise price: $34.35 per share
Post-grant derivative holdings: 17,084 derivative securities
+1 more
4 metrics
Option grant size
17,084 shares
Stock options on Class A common stock granted to director
Exercise price
$34.35 per share
Strike price of newly granted stock options
Post-grant derivative holdings
17,084 derivative securities
Total options held following the transaction
Option expiration
May 20, 2036
Expiration date of the stock option award
Key Terms
Stock Option (right to buy), Class A Common Stock, change in control, annual stockholder meeting, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
Class A Common Stock financial
"underlying_security_title: Class A Common Stock"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
change in control financial
"the shares will vest in full upon a change in control"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
annual stockholder meeting financial
"the date of the Company's 2027 annual stockholder meeting"
An annual stockholder meeting is a yearly gathering where a company's owners (shareholders) receive updates on performance, vote on key issues like board members, executive pay and major corporate plans, and ask questions of management. Think of it as a company town hall where choices about oversight and direction are decided; outcomes can affect management accountability, corporate strategy and ultimately the value and risks of investors’ shares.
vesting financial
"The shares subject to the option will vest in full"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Vera Therapeutics (VERA) disclose about Scott W. Morrison’s recent equity grant?
Vera Therapeutics reported that director Scott W. Morrison received a stock option grant for 17,084 shares of Class A common stock. The options were awarded as compensation and are exercisable at $34.35 per share, subject to specific vesting conditions tied to time and corporate events.
What is the exercise price of Scott W. Morrison’s Vera Therapeutics (VERA) stock options?
The stock options granted to Scott W. Morrison have an exercise price of $34.35 per share. This means he can purchase Vera Therapeutics Class A common stock at $34.35 once the options are vested and exercisable, subject to the grant’s vesting schedule and expiration date in 2036.
When do Scott W. Morrison’s Vera Therapeutics (VERA) options vest?
The options vest in full on the earlier of the first anniversary of the grant date or the date of Vera Therapeutics’ 2027 annual stockholder meeting. Vesting is contingent on Morrison’s continuous service with the company through that date, as specified in the grant terms.
What happens to Scott W. Morrison’s Vera Therapeutics (VERA) options if there is a change in control?
If Vera Therapeutics undergoes a change in control, Scott W. Morrison’s options will vest in full on that date. This accelerated vesting is conditioned on his continuous service with the company through the change-in-control date, according to the footnote describing the award’s terms.
Are Scott W. Morrison’s Vera Therapeutics (VERA) options an open-market stock purchase?
No, the transaction is a grant of stock options as compensation, not an open-market stock purchase. The Form 4 describes it with transaction code A, indicating an award or other acquisition, with no cash price paid at grant and vesting based on service conditions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
